Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT ID: NCT01520246
Last Updated: 2016-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies gene expression in samples from patients with T-cell acute lymphoblastic leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
NCT01500499
Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia
NCT01057095
Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01626183
Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia
NCT01653613
Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01139333
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To test whether the tumor suppressor candidate gene PDLIM2 is downregulated in human cancers such as T-cell acute lymphoblastic leukemia (T-ALL) and to use the human T-lymphotropic virus 1 (HTLV-1)-mediated in vitro transformation of human T cells as control.
OUTLINE: Previously collected cancer and control tissues are analyzed for the expression patterns of PDLIM2 and other control genes. Human T-cells isolated from human blood are also co-cultured with HTLV-1-transformed T-cell lines.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gene expression analysis
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Specimens (e.g., tissue, blood, and bodily fluids) of various cancer cells and or tissues from de-identified patients such as T-cell acute lymphoblastic leukemia (T-ALL)
* Normal control tissue
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gutian Xiao, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AALL12B2
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000723902
Identifier Type: OTHER
Identifier Source: secondary_id
AALL12B2
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-00241
Identifier Type: REGISTRY
Identifier Source: secondary_id
AALL12B2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.